X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5856) 5856
rituximab (5380) 5380
male (3377) 3377
female (3348) 3348
middle aged (2853) 2853
antibodies, monoclonal, murine-derived (2793) 2793
aged (2311) 2311
adult (2291) 2291
treatment outcome (1940) 1940
antineoplastic combined chemotherapy protocols - therapeutic use (1917) 1917
antibodies, monoclonal, murine-derived - administration & dosage (1895) 1895
hematology (1848) 1848
oncology (1791) 1791
antibodies, monoclonal - administration & dosage (1641) 1641
antibodies, monoclonal - therapeutic use (1548) 1548
cyclophosphamide - administration & dosage (1424) 1424
antibodies, monoclonal, murine-derived - therapeutic use (1273) 1273
therapy (1196) 1196
antineoplastic combined chemotherapy protocols - administration & dosage (1143) 1143
vincristine - administration & dosage (1141) 1141
doxorubicin - administration & dosage (1080) 1080
prednisone - administration & dosage (993) 993
aged, 80 and over (937) 937
chemotherapy (934) 934
non-hodgkins-lymphoma (907) 907
lymphoma, large b-cell, diffuse - drug therapy (886) 886
lymphomas (770) 770
cancer (753) 753
antineoplastic agents - therapeutic use (733) 733
antibodies, monoclonal, murine-derived - adverse effects (723) 723
remission induction (691) 691
retrospective studies (684) 684
care and treatment (678) 678
prognosis (674) 674
disease-free survival (651) 651
antibodies, monoclonal - adverse effects (622) 622
antineoplastic agents - administration & dosage (618) 618
transplantation (600) 600
adolescent (584) 584
immunologic factors - therapeutic use (581) 581
young adult (577) 577
cyclophosphamide (572) 572
lymphoma (572) 572
medicine & public health (558) 558
antineoplastic combined chemotherapy protocols - adverse effects (549) 549
animals (542) 542
anti-cd20 monoclonal-antibody (536) 536
follow-up studies (535) 535
recurrence (534) 534
drug administration schedule (528) 528
immunology (468) 468
lymphoma, b-cell - drug therapy (458) 458
cyclophosphamide - therapeutic use (457) 457
drug therapy (434) 434
combined modality therapy (432) 432
rheumatology (429) 429
abridged index medicus (427) 427
lymphoma, non-hodgkin - drug therapy (422) 422
immunotherapy (419) 419
immunosuppressive agents - therapeutic use (406) 406
b-cell lymphoma (396) 396
antineoplastic agents (388) 388
trial (384) 384
efficacy (381) 381
time factors (381) 381
lymphoma, large b-cell, diffuse - pathology (378) 378
immunologic factors - administration & dosage (377) 377
lymphoma, follicular - drug therapy (375) 375
prednisone - therapeutic use (375) 375
drug therapy, combination (374) 374
leukemia, lymphocytic, chronic, b-cell - drug therapy (373) 373
survival (370) 370
antimitotic agents (369) 369
risk factors (363) 363
disease (349) 349
antigens, cd20 - immunology (345) 345
research (344) 344
vincristine - therapeutic use (344) 344
b-lymphocytes - immunology (342) 342
mice (341) 341
elderly-patients (339) 339
monoclonal antibodies (335) 335
analysis (330) 330
survival analysis (329) 329
doxorubicin - therapeutic use (328) 328
antineoplastic agents - adverse effects (327) 327
health aspects (322) 322
vidarabine - analogs & derivatives (314) 314
antibodies (310) 310
cyclophosphamide - adverse effects (309) 309
follicular lymphoma (308) 308
survival rate (308) 308
chronic lymphocytic-leukemia (292) 292
b-lymphocytes - drug effects (290) 290
child (290) 290
hemic and lymphatic diseases (288) 288
neoplasm staging (285) 285
monoclonal-antibody (281) 281
dose-response relationship, drug (277) 277
arthritis, rheumatoid - drug therapy (275) 275
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5708) 5708
Japanese (206) 206
German (56) 56
French (55) 55
Spanish (48) 48
Chinese (32) 32
Russian (30) 30
Hungarian (17) 17
Italian (8) 8
Polish (6) 6
Czech (5) 5
Norwegian (4) 4
Danish (3) 3
Dutch (3) 3
Finnish (3) 3
Portuguese (2) 2
Bosnian (1) 1
Croatian (1) 1
Hebrew (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 25, pp. 5996 - 6004
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
Summary Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of transplant recipients and can be Epstein–Barr virus (EBV)... 
Hematology, Oncology and Palliative Medicine | SOLID-ORGAN TRANSPLANTATION | VIRAL LOAD | THERAPY | MANAGEMENT | REDUCTION | ONCOLOGY | IMMUNOSUPPRESSION | DISEASE | LYMPHOMA | RISK | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 5, pp. 417 - 427
This study of ANCA-associated vasculitis compared a single course of rituximab with conventional immunosuppression with cyclophosphamide followed by... 
WEGENERS-GRANULOMATOSIS | MAINTENANCE | ANTIBODY-ASSOCIATED VASCULITIS | RENAL VASCULITIS | CYCLOPHOSPHAMIDE | RITUXIMAB | ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES | RANDOMIZED-TRIAL | SYSTEMIC VASCULITIDES | CELL-ACTIVATION | MEDICINE, GENERAL & INTERNAL | ACTIVATION | SPECIFICITY | PROTEINASE-3 | LYMPHOCYTES | Recurrence | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Double-Blind Method | Drug Administration Schedule | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | B-Lymphocytes | Rituximab | Cyclophosphamide - adverse effects | Remission Induction | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Cyclophosphamide - therapeutic use | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Drug Therapy, Combination | Antibodies, Monoclonal, Murine-Derived - adverse effects | Azathioprine - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Immunosuppression | Vasculitis | Drug therapy | Patient outcomes | Disease | Medical treatment | Hypersensitivity | Patients | Immunosuppressive agents | Cyclophosphamide | Infectious diseases | Lymphocytes B | Antineutrophil cytoplasmic antibodies | Remission | Azathioprine
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 6, pp. 520 - 531
...) combined with the anti-CD20 monoclonal antibody rituximab (e.g., R-CHOP). 2 – 4 Only a minority of patients have a complete remission, and relapse or progression usually occurs within 2 to 3 years, resulting in an overall survival of less than 5 years. To improve this grim prognosis, . . . 
SURVIVAL | FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | RITUXIMAB | COMBINATION | FLUDARABINE | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 02/2014, Volume 289, Issue 7, pp. 4273 - 4285
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 28, pp. 3096 - 3102
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2011, Volume 29, Issue 23, pp. 3194 - 3200
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 424 - 435
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 5, pp. 573 - 583
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0332, 2015, Volume 54, Issue 7, pp. 1153 - 1160
.... At the first RTX administration, ongoing immunosuppressives were withdrawn. Results. Sixty-nine patients were identified, 67 of whom were failing other therapies... 
Biologic therapies | Microscopic polyangiitis | Vasculitis | Maintenance treatment | Granulomatosis with polyangiitis | B cells | Anti-neutrophil cytoplasm antibody | granulomatosis with polyangiitis | biologic therapies | microscopic polyangiitis | vasculitis | anti-neutrophil cytoplasm antibody | maintenance treatment | WEGENERS-GRANULOMATOSIS | RHEUMATOID-ARTHRITIS | ANTIBODY-ASSOCIATED VASCULITIS | MANAGEMENT | CYCLOPHOSPHAMIDE | DEPLETION | PERIPHERAL-BLOOD | POLYMORPHISM | RHEUMATOLOGY | B-CELLS | REMISSION-INDUCTION | Recurrence | Prednisolone - administration & dosage | Follow-Up Studies | Antirheumatic Agents - administration & dosage | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Incidence | Dose-Response Relationship, Drug | Time Factors | Antirheumatic Agents - adverse effects | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Antirheumatic Agents - therapeutic use | Drug Administration Schedule | Rituximab | Treatment Outcome | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Longitudinal Studies | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Cohort Studies | Clinical Science
Journal Article